AbbVie Juvederm Collection — Net revenues decreased by 1.6% to $249.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 10.8%, from $279.00M to $249.00M. Over 4 years (FY 2021 to FY 2025), Juvederm Collection — Net revenues shows a downward trend with a -10.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase in revenue signals strong consumer demand and successful market penetration in the aesthetics sector, while a decrease may indicate increased competition or shifting consumer preferences.
This metric represents the total gross sales of the Juvederm product line minus returns, allowances, and discounts. It s...
Comparable to revenue reporting for specific high-growth aesthetic or consumer-health product lines at peer pharmaceutical or medical device companies.
abbv_segment_juvederm_collection_net_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $428.00M | $354.00M | $432.00M | $410.00M | $344.00M | $352.00M | $322.00M | $355.00M | $368.00M | $321.00M | $334.00M | $297.00M | $343.00M | $258.00M | $279.00M | $231.00M | $260.00M | $253.00M | $249.00M |
| QoQ Change | — | -17.3% | +22.0% | -5.1% | -16.1% | +2.3% | -8.5% | +10.2% | +3.7% | -12.8% | +4.0% | -11.1% | +15.5% | -24.8% | +8.1% | -17.2% | +12.6% | -2.7% | -1.6% |
| YoY Change | — | — | — | — | -19.6% | -0.6% | -25.5% | -13.4% | +7.0% | -8.8% | +3.7% | -16.3% | -6.8% | -19.6% | -16.5% | -22.2% | -24.2% | -1.9% | -10.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.